Article
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Molecular cancer therapeutics - 1 Oct 2013
Wheler Jennifer J, Tsimberidou Apostolia M, Falchook Gerald S, Zinner Ralph G, Hong David S, Fok Jansina Y, Fu Siqing, Piha-Paul Sarina A, Naing Aung, Kurzrock Razelle
Abstract excerpt
Preclinical data suggest that combined EGF receptor (EGFR) targeting with an EGFR tyrosine kinase inhibitor and an anti-EGFR monoclonal antibody may be superior over single-agent targeting. Therefore, as part of a phase I study, we analyzed the outcome of 20 patients with non-small cell lung cancer treated with the combination of erlotinib and cetuximab. EGFR mutation status was ascertained in a Clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.